Warm Autoimmune Hemolytic Anemia Waiha Market

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease,historical &forecasted epidemiology as well as the market trends of WAIHAs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.


The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Warm Autoimmune Hemolytic Anemia (WAIHA) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2017–2030

Warm Autoimmune Hemolytic Anemia (WAIHA) - Disease Understanding and Treatment Algorithm

Warm Autoimmune Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs which can be idiopathic (primary) or secondary. In w-AIHA, the autoantibodies react optimally with the RBCs at 37°C. In typical cases, no specific antibody can be identified since theyare polyclonal and react with all RBCs tested (pan-reactive), even when w-AIHA complicates a clonal B-cell lymphoproliferative disorder like CLL. The traditional treatment options for WAIHA include corticosteroids, splenectomy,and conventional immunosuppressive drugs.


The DelveInsight Warm Autoimmune Hemolytic Anemia (WAIHA) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Warm Autoimmune Hemolytic Anemia.

Warm Autoimmune Hemolytic Anemia Epidemiology

The Warm Autoimmune Hemolytic Anemia (WAIHA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of AIHA, Diagnosed Prevalence of wAIHA, Type-specific Prevalence of wAIHA, Gender-specific Prevalence of wAIHA) scenario of Warm Autoimmune Hemolytic Anemia (WAIHA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.


According to DelveInsight, the total number of prevalent cases of Warm Autoimmune Hemolytic Anemia (WAIHA) in 7 MM was found to be 82,045 in the year 2017.

Warm Autoimmune Hemolytic Anemia Drug Chapters

This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Currently, affected individuals are usually treated with corticosteroid drugs such as prednisone and can usually be well controlled with proper treatment. For individuals who do not respond to corticosteroid therapy or develop intolerable side effects, immunosuppressive drugs may be administered, or surgical removal of the spleen (splenectomy) may be performed. Over the years,however, newer options have become available with considerable evidence of success. They are used mainly in patients who fail to respond to splenectomy, those who relapse after splenectomy, and those who cannot maintain stable hemoglobin levels without unacceptably high doses of corticosteroids.

Warm Autoimmune Hemolytic Anemia Market Outlook

The Warm Autoimmune Hemolytic Anemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the market of Warm Autoimmune Hemolytic Anemia in 7MM was found to be USD 368 Million in 2017, and is expected to increase during the course of the study period (2017–2030).


The market for Warm Autoimmune Hemolytic Anemia is expected to increase with a CAGR of 5.20% for 7MM. Among the 7MM, the United States accounts for the largest market size of WAIHA, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Warm Autoimmune Hemolytic Anemia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Warm Autoimmune Hemolytic Anemia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Warm Autoimmune Hemolytic Anemia Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Warm Autoimmune Hemolytic Anemia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Warm Autoimmune Hemolytic Anemia market
  • • Organize sales and marketing efforts by identifying the best opportunities for Warm Autoimmune Hemolytic Anemia market
  • • To understand the future market competition in the Warm Autoimmune Hemolytic Anemia market.


What is Warm Autoimmune Hemolytic Anemia?

Warm Antibody Hemolytic Anemia (WAIHA) is an autoimmune disorder characterized by the premature destruction of healthy red blood cells by autoantibodies. It is a common disorder directed against self RBCs.


What was the Warm Autoimmune Hemolytic Anemia market size in the 7 major markets (MM) in 2017?

Warm Autoimmune Hemolytic Anemia market size in 7MM was USD 368 million in 2017.


What was the total prevalent population of Warm Autoimmune Hemolytic Anemia in the 7MM in 2017?

The total Warm Autoimmune Hemolytic Anemia prevalent population in 7MM was 82,045 in 2017.


What are the market drivers of Warm Autoimmune Hemolytic Anemia?

Increased market opportunity, increasing awareness, and an increase in the number of research initiatives are the market drivers of Warm Autoimmune Hemolytic Anemia.


What are the market barriers of Warm Autoimmune Hemolytic Anemia?

Diagnostic delays in the case of idiopathic WAIHA, lack of approved therapies, and chances of relapse are the market barriers of Warm Autoimmune Hemolytic Anemia.


Which are the emerging therapies in the Warm Autoimmune Hemolytic Anemia market?

Fostamatinib, APL-2, M281, IMVT-1401, ALXN1830/SYNT001, BIV009 (Sutimlimab) are the emerging therapies in the Warm Autoimmune Hemolytic Anemia market.


Which are the leading companies in the Warm Autoimmune Hemolytic Anemia market? 

Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc, Momenta Pharmaceuticals, Immunovant, Alexion Pharmaceuticals, Inc, Sanofi are the leading companies in the Warm Autoimmune Hemolytic Anemia market.


How is epidemiology segmented for Warm Autoimmune Hemolytic Anemia?

Warm Autoimmune Hemolytic Anemia Epidemiology is segmented as Total Prevalent Cases of AIHA, Diagnosed Prevalence of WAIHA, Type-specific Prevalence of WAIHA, and Gender-specific Prevalence of WAIHA in the 7MM from 2017 to 2030.

1. Key Insights

2. Executive Summary

3. SWOT Analysis

4. wAIHA Market Overview at a Glance

4.1. Market Share (%) Distribution of wAIHA in 2017

4.2. Market Share (%) Distribution of wAIHA in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Types

5.3. Causes

5.4. Signs and Symptoms

5.5. Pathophysiology

5.6. Manifestations

5.7. Diagnosis

  • Immunohematological assessment of patients with AIHA
  • DAT-negative AIHA

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. KOL Views

6.3. 7MM Total Prevalent Patient Population of wAIHA

6.4. Assumptions and Rationale: 7MM

7. Country Wise-Epidemiology of wAIHA

7.1. The United States

7.1.1. Total Prevalent Cases of AIHA in the United States

7.1.2. Diagnosed Prevalence of wAIHA in the United States

7.1.3. Type-specific Prevalence of wAIHA in the United States

7.1.4. Gender-specific Prevalence of wAIHA in the United States

7.2. EU5

7.2.1. Germany

7.2.1.1. Total Prevalent Cases of AIHA in Germany

7.2.1.2. Diagnosed Prevalence of wAIHA in Germany

7.2.1.3. Type-specific Prevalence of wAIHA in Germany

7.2.1.4. Gender-specific Prevalence of wAIHA in Germany

7.2.2. France

7.2.2.1. Total Prevalent Cases of AIHA in France

7.2.2.2. Diagnosed Prevalence of wAIHA in France

7.2.2.3. Type-specific Prevalence of wAIHA in France

7.2.2.4. Gender-specific Prevalence of wAIHA in France

7.2.3. Italy

7.2.3.1. Total Prevalent Cases of AIHA in Italy

7.2.3.2. Diagnosed Prevalence of wAIHA in Italy

7.2.3.3. Type-specific Prevalence of wAIHA in Italy

7.2.3.4. Gender-specific Prevalence of wAIHA in Italy

7.2.4. Spain

7.2.4.1. Total Prevalent Cases of AIHA in Spain

7.2.4.2. Diagnosed Prevalence of wAIHA in Spain

7.2.4.3. Type-specific Prevalence of wAIHA in Spain

7.2.4.4. Gender-specific Prevalence of wAIHA in Spain

7.2.5. The United Kingdom

7.2.5.1. Total Prevalent Cases of AIHA in the UK

7.2.5.2. Diagnosed Prevalence of wAIHA in the UK

7.2.5.3. Type-specific Prevalence of wAIHA in the UK

7.2.5.4. Gender-specific Prevalence of wAIHA in the UK

7.3. Japan

7.3.1. Total Prevalent Cases of AIHA in Japan

7.3.2. Diagnosed Prevalence of wAIHA in Japan

7.3.3. Type-specific Prevalence of wAIHA in Japan

7.3.4. Gender-specific Prevalence of wAIHA in Japan

8. Treatment and Management of wAIHA

8.1. Sequential approach to treatment options for w-AIHA and common dosing regimens

8.1.1. First-line therapy

8.1.1.1. Corticosteroids

8.1.2. Second-line therapy

8.1.2.1. Splenectomy

8.1.2.2. Rituximab

8.1.2.3. Immunosuppressive drugs

8.1.2.4. Other Options

8.2. British Guidelines for WAIHA treatment

9. Case Study

10. Patient Journey

12. Unmet Needs

13. Emerging Therapies

13.1. Fostamatinib: Rigel Pharmaceuticals

13.1.1. Product Description

13.1.2. Other Development Activities

13.1.3. Clinical Development

13.1.3.1. Clinical Trials Information

13.1.4. Safety and Efficacy

13.2. APL-2: Apellis Pharmaceuticals, Inc.

13.2.1. Product Description

13.2.2. Other Development Activities

13.2.3. Clinical Development

13.2.3.1. Clinical Trials Information

13.2.4. Safety and Efficacy

13.3. M281: Momenta Pharmaceuticals

13.3.1. Product Description

13.3.2. Other Development Activities

13.3.3. Clinical Development

13.3.3.1. Clinical Trials Information

13.3.4. Safety and Efficacy

13.4. IMVT-1401: Immunovant

13.4.1. Product Description

13.4.2. Other Development Activities

13.4.3. Clinical Development

13.4.3.1. Clinical Trials Information

13.4.4. Safety and Efficacy

13.5. ALXN1830/SYNT001: Alexion Pharmaceuticals, Inc.

13.5.1. Product Description

13.5.2. Other Development Activities

13.5.3. Clinical Development

13.5.4. Clinical Trials Information

13.5.5. Product Profile

14. Other Promising Candidates

14.1. BIV009 (Sutimlimab): Sanofi

14.1.1. Product Description

14.1.2. Other Development Activities

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Safety and Efficacy

14.1.6. Product Profile

15. wAIHA: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of wAIHA in 7MM

15.3. KOL Views

16. Market Outlook by Country

16.1. The United States: Market Outlook

16.2. United States Market Size

16.2.1. Total Market Size of wAIHA

16.2.2. Market Size of wAIHA by Therapies

17. EU-5 Countries: Market Outlook

17.1. Germany

17.1.1. Total Market size of wAIHA

17.1.2. Market Size of wAIHA by Therapies

17.2. France

17.2.1. Total Market Size of wAIHA

17.2.2. Market Size of wAIHA by Therapies

17.3. Italy

17.3.1. Total Market Size of wAIHA

17.3.2. Market Size of wAIHA by Emerging Therapies

17.4. Spain

17.4.1. Total Market Size of wAIHA

17.4.2. Market Size of wAIHA by Therapies

17.5. United Kingdom

17.5.1. Total Market Size of wAIHA

17.5.2. Market Size of wAIHA by Therapies

18. Japan: Market Outlook

18.1.1. Total Market Size of wAIHA

18.1.2. Market Size of wAIHA by Therapies

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

Table 1: Classification of wAIHA

Table 2: Prevalent Patient Population of wAIHA in 7MM (2017-2030)

Table 3: Total Prevalent Cases of AIHA in the United States (2017-2030)

Table 4: Diagnosed Prevalence of wAIHA in the United States (2017-2030)

Table 5: Type-specific Prevalence of wAIHA in the United States (2017-2030)

Table 6: Gender-specific Prevalence of wAIHA in the United States (2017-2030)

Table 7: Total Prevalent Cases of AIHA in Germany (2017-2030)

Table 8: Diagnosed Prevalence of wAIHA in Germany (2017-2030)

Table 9: Type-specific Prevalence of wAIHA in Germany (2017-2030)

Table 10: Gender-specific Prevalence of wAIHA in Germany (2017-2030)

Table 11: Total Prevalent Cases of AIHA in France (2017-2030)

Table 12: Diagnosed Prevalence of wAIHA in France (2017-2030)

Table 13: Type-specific Prevalence of wAIHA in France (2017-2030)

Table 14: Gender-specific Prevalence of wAIHA in France (2017-2030)

Table 15: Total Prevalent Cases of AIHA in Italy (2017-2030)

Table 16: Diagnosed Prevalence of wAIHA in Italy (2017-2030)

Table 17: Type-specific Prevalence of wAIHA in Italy (2017-2030)

Table 18: Gender-specific Prevalence of wAIHA in Italy (2017-2030)

Table 19: Total Prevalent Cases of AIHA in Spain (2017-2030)

Table 20: Diagnosed Prevalence of wAIHA in Spain (2017-2030)

Table 21: Type-specific Prevalence of wAIHA in Spain (2017-2030)

Table 22: Gender-specific Prevalence of wAIHA in Spain (2017-2030)

Table 23: Total Prevalent Cases of AIHA in the United Kingdom (2017-2030)

Table 24: Diagnosed Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 25: Type-specific Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 26: Gender-specific Prevalence of wAIHA in the United Kingdom (2017-2030)

Table 27: Total Prevalent Cases of AIHA in Japan (2017-2030)

Table 28: Diagnosed Prevalence of wAIHA in Japan (2017-2030)

Table 29: Type-specific Prevalence of wAIHA in Japan (2017-2030)

Table 30: Gender-specific Prevalence of wAIHA in Japan (2017-2030)

Table 31: Treatment Flow

Table 32: Fostamatinib, Clinical Trial Description, 2020

Table 33: APL-2, Clinical Trial Description, 2020

Table 34: M281, Clinical Trial Description, 2019

Table 35: RVT-1401, Clinical Trial Description, 2020

Table 36: SYNT001, Clinical Trial Description, 2020

Table 37: BIV009, Clinical Trial Description, 2020

Table 38: 7 Major Market Size of wAIHA in USD Million (2017-2030)

Table 39: United States Market Size of wAIHA in USD Million (2017-2030)

Table 40: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 41: Germany Market Size of wAIHA in USD Million (2017-2030)

Table 42: Germany Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 43: France Market Size of wAIHA in USD Million (2017-2030)

Table 44: France Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 45: Italy Market Size of wAIHA in USD Million (2017-2030)

Table 46: Italy Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 47: Spain Market Size of wAIHA in USD Million (2017-2030)

Table 48: Spain Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 49: United Kingdom Market Size of wAIHA in USD Million (2017-2030)

Table 50: UK Market Size of wAIHA by Therapies in USD Million (2017-2030)

Table 51: Japan Market Size of wAIHA in USD Million (2017-2030)

Table 52: Japan Market Size of wAIHA by Therapies in USD Million (2017-2030)


List of figures

Figure 1: SWOT Analysis of wAIHa

Figure 2 : Mechanisms of hemolysis in warm antibody autoimmune hemoytic anemia

Figure 3: Clinical-serologic associations with the direct Coombs test

Figure 4: Prevalent Patient Population of wAIHA in 7MM (2017-2030)

Figure 5: Total Prevalent Cases of AIHA in the United States (2017-2030)

Figure 6: Diagnosed Prevalence of wAIHA in the United States (2017-2030)

Figure 7: Type-specific Prevalence of wAIHA in the United States (2017-2030)

Figure 8: Gender-specific Prevalence of wAIHA in the United States (2017-2030)

Figure 9: Total Prevalent Cases of AIHA in Germany (2017-2030)

Figure 10: Diagnosed Prevalence of wAIHA in Germany (2017-2030)

Figure 11: Type-specific Prevalence of wAIHA in Germany (2017-2030)

Figure 12: Gender-specific Prevalence of wAIHA in Germany (2017-2030)

Figure 13: Total Prevalent Cases of AIHA in France (2017-2030)

Figure 14:Diagnosed Prevalence of wAIHA in France (2017-2030)

Figure 15: Type-specific Prevalence of wAIHA in France (2017-2030)

Figure 16: Gender-specific Prevalence of wAIHA in France (2017-2030)

Figure 17: Total Prevalent Cases of AIHA in Italy (2017-2030)

Figure 18: Diagnosed Prevalence of wAIHA in Italy (2017-2030)

Figure 19: Type-specific Prevalence of wAIHA in Italy (2017-2030)

Figure 20: Gender-specific Prevalence of wAIHA in Italy (2017-2030)

Figure 21: Total Prevalent Cases of AIHA in Spain (2017-2030)

Figure 22: Diagnosed Prevalence of wAIHA in Spain (2017-2030)

Figure 23: Type-specific Prevalence of wAIHA in Spain (2017-2030)

Figure 24: Gender-specific Prevalence of wAIHA in Spain (2017-2030)

Figure 25: Total Prevalent Cases of AIHA in the UK (2017-2030)

Figure 26: Diagnosed Prevalence of wAIHA in the UK (2017-2030)

Figure 27: Type-specific Prevalence of wAIHA in the UK (2017-2030)

Figure 28: Gender-specific Prevalence of wAIHA in the UK (2017-2030)

Figure 29: Total Prevalent Cases of AIHA in Japan (2017-2030)

Figure 30: Diagnosed Prevalence of wAIHA in Japan (2017-2030)

Figure 31: Type-specific Prevalence of wAIHA in Japan (2017-2030)

Figure 32: Gender-specific Prevalence of wAIHA in Japan (2017-2030)

Figure 33: Treatment algorithm for warm AIHA in adults

Figure 34: Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia

Figure 35: Unmet Needs of wAIHA

Figure 36: 7 Major Market Size of wAIHA in USD Million (2017-2030)

Figure 37: Market Size of wAIHA in the United States, USD Million (2017-2030)

Figure 38: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 39: Market Size of wAIHA in Germany, USD Million (2017-2030)

Figure 40: The US Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 41: Market Size of wAIHA in France USD Million (2017-2030)

Figure 42: The US Market Size of wAIHA by Emerging Therapies in USD Million (2017-2030)

Figure 43: Market Size of wAIHA in Italy, USD Million (2017-2030)

Figure 44: Italy Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 45: Market Size of wAIHA in Spain, USD Million (2017-2030)

Figure 46: Spain Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 47: Market Size of wAIHA in the United Kingdom, USD Million (2017-2030)

Figure 48: UK Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 49: Market Size of wAIHA in Japan, USD Million (2017-2030)

Figure 50: Japan Market Size of wAIHA by Therapies in USD Million (2017-2030)

Figure 51: Market Drivers

Figure 52: Market Barriers

• Rigel Pharmaceuticals

• Apellis Pharmaceuticals, Inc.

• Momenta Pharmaceuticals

• Immunovant

• Alexion Pharmaceuticals, Inc.

  • Tags:
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (w...
  • Warm Autoimmune Hemolytic Anemia (...

Forward to Friend

Need A Quote